Canada markets closed

Khiron Life Sciences Corp. (KHRN.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
0.1350-0.0050 (-3.57%)
At close: 02:37PM EST
Full screen
Previous Close0.1400
Open0.1350
Bid0.1300 x 0
Ask0.1400 x 0
Day's Range0.1350 - 0.1350
52 Week Range0.0450 - 0.2800
Volume123,015
Avg. Volume189,933
Market Cap29.212M
Beta (5Y Monthly)2.12
PE Ratio (TTM)N/A
EPS (TTM)-0.1920
Earnings DateMay 01, 2023 - May 05, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est0.10
  • CNW Group

    Khiron begins dispensation of insurance-covered prescriptions in Colombia

    Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC), announces that it has begun dispensing medical cannabis to patients in its wholly owned ZereniaTM clinic, under the insurance coverage system approved by the Government of Colombia on January 1st, 2023.

  • CNW Group

    NHS reimburses the cost of cannabis treatment to the first Zerenia™ Clinics UK patient

    Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC), continues to spearhead the medical cannabis market in the United Kingdom by successfully attaining, for the first time, full reimbursement by the NHS of costs associated to cannabis-based medication and clinic fees for a patient enrolled in Zerenia™ Clinics UK. The patient was referred to the team at Zerenia™ Clinics UK for assistance with evaluation and advice on cannabis-based treatment opti

  • CNW Group

    Khiron wins first medical cannabis contract with Colombia's largest public insurance company

    Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC), continues to pioneer the medical cannabis market in LATAM by announcing that Zerenia has signed a contract with insurance CAPITAL SALUD EPS, to provide medical cannabis services and products to CAPITAL SALUD EPS patient population and has already begun treating the first cohort of patients. Under the contract, CAPITAL SALUD EPS patients will get access to Khiron's products and clinical service